A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 55 sites in 11 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 5th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2022.
This study's enrollment of 1,484 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 7th largest by enrollment, is one of 5 that started in 2022, is one of 31 in phase 3, and was the 39th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, double-blind, active comparator-controlled study of the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-naïve adults 50 years of age and older. The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator. In addition to studying safety/tolerability, it is hypothesized that, at 30 days postvaccination, the immunogenicity of V116 is noninferior to PPSV23 for the 12 common serotypes in V116 and PPSV23, and that V116 is superior to PPSV23 for the 9 serotypes unique to V116. It is also hypothesized that V116 is superior to PPSV23 in the percentage of participants with ≥4-fold rise from baseline in unique V116 serotypes, as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs).
Selected participants may be eligible for optional immunogenicity or PBMC substudies extension that will investigate the exploratory objectives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single intramuscular (IM) vaccination of 0.5 mL of V116 on Day 1.
Biological: V116
Participants will receive a single IM vaccination of 0.5 mL of PPSV23 on Day 1.
Biological: PPSV23
Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
Also known as: PNEUMOVAX™23
Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of pain/tenderness, redness/erythema, and swelling. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.
Time frame: Up to 5 days postvaccination
Percentage of Participants With Solicited Systemic AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C). 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.
Time frame: Up to 5 days postvaccination
Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.
Time frame: Up to 6 months postvaccination
Serotype-Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs) for All Serotypes in V116
Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs), and they hypothesis test (1-sided p-value), were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.
Time frame: Day 30 postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific OPAs for Serotypes Unique to V116
The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the unique pneumococcal serotypes contained in V116 was determined. The 9 unique pneumococcal serotypes in V116 are as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Percentage of Participants With ≥4-fold Rise From Baseline in Serotype-Specific Cross-Reactive OPAs
OPA induced by serotypes 6A and 15C in V116 but cross-reactive to serotypes 6C and 15B, respectively, were measured. The percentage of participants with ≥4-fold rise from baseline in serotype-specific cross-reactive OPAs was determined. Point estimate, 95% CI, and p-value are based on the Clopper-Pearson method. Per protocol, this outcome measure was not planned or analyzed in the PPSV23 study arm.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Serotype-Specific Geometric Mean Fold Rise (GMFR) of OPA GMTs for All Serotypes in V116
The GMFR from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined using MOPA. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Serotype-Specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for All Serotypes in V116
The GMCs for serotype-specific IgG antibodies for all serotypes in V116 were determined using pneumococcal electrochemiluminescence (PnECL). The GMC ratio estimation and 95% CI were calculated using a cLDA method. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.
Time frame: Day 30 postvaccination
Serotype-Specific GMFR of IgG GMCs for All Serotypes in V116
The GMFR from baseline in GMCs for serotype-specific IgG antibodies for all serotypes in V116 was determined using PnECL. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific OPA GMTs for All Serotypes in V116
The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined with MOPA. The within-group CIs were calculated based on the Clopper-Pearson method.
Time frame: Baseline (Day 1) and Day 30 postvaccination
Percentage of Participants With ≥4-Fold Rise From Baseline in Serotype-Specific IgG GMCs for All Serotypes in V116
The percentage of participants with ≥4-fold rise from baseline in serotype-specific IgG GMCs for all serotypes in V116 was determined using PnECL. The within-group CIs were calculated based on the Clopper-Pearson method.
Time frame: Baseline (Day 1) and Day 30 postvaccination
| Milestone | V116 | PPSV23 |
|---|---|---|
| Started | 741 | 743 |
| Vaccinated | 739 | 741 |
| Completed | 733 | 735 |
| Not completed | 8 | 8 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Milestone | V116 | PPSV23 |
|---|---|---|
| Started | 350 | 350 |
| Vaccinated | 349 | 348 |
| Completed | 335 | 338 |
| Not completed | 15 | 12 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Randomized by mistake without study treatment | 0 | 2 |
| Withdrew: Withdrawal by subject | 12 | 5 |
| Withdrew: Non-study pneumococcal vaccine administered | 0 | 1 |
| Milestone | V116 | PPSV23 |
|---|---|---|
| Started | 41 | 39 |
| Vaccinated | 41 | 39 |
| Completed | 39 | 39 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs consisted of pain/tenderness, redness/erythema, and swelling. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| Injection site erythema | 4.7 | 6.3 |
| Injection site pain | 39.0 | 35.2 |
| Injection site swelling | 4.9 | 4.3 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs consist of the following: fatigue (tiredness), headache, myalgia (muscle aches), and pyrexia (maximum temperature ≥ 100.4 °F/38.0 °C). 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| Fatigue | 16.5 | 15.7 |
| Headache | 13.7 | 12.0 |
| Myalgia | 5.3 | 5.9 |
| Pyrexia | 1.1 | 1.3 |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an other important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination are summarized. 95% confidence intervals (CIs) for between-group differences are provided using the Miettinen \& Nurminen method.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs) | 0 | 0 |
Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs), and they hypothesis test (1-sided p-value), were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.
| Titers | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 3 | 230.4 (NA to NA) | 211.5 (NA to NA) |
| 7F | 4876.7 (NA to NA) | 3314.6 (NA to NA) |
| 8 | 3379.6 (NA to NA) | 2882.1 (NA to NA) |
| 9N | 7346.6 (NA to NA) | 6545.9 (NA to NA) |
| 10A | 4382.9 (NA to NA) | 2818.7 (NA to NA) |
| 11A | 3711.1 (NA to NA) | 1809.7 (NA to NA) |
| 12F | 3031.8 (NA to NA) | 1854.9 (NA to NA) |
| 17F | 8215.7 (NA to NA) | 4060.5 (NA to NA) |
| 19A | 2670.0 (NA to NA) | 1879.9 (NA to NA) |
| 20A | 6966.1 (NA to NA) | 4208.4 (NA to NA) |
| 22F | 4724.1 (NA to NA) | 3084.9 (NA to NA) |
| 33F | 15497.3 (NA to NA) | 17483.0 (NA to NA) |
| 6A | 3193.9 (NA to NA) | 964.0 (NA to NA) |
| 15A | 6746.5 (NA to NA) | 1462.1 (NA to NA) |
| 15C | 7604.8 (NA to NA) | 2605.0 (NA to NA) |
| 16F | 6675.4 (NA to NA) | 1482.2 (NA to NA) |
| 23A | 4804.2 (NA to NA) | 837.2 (NA to NA) |
| 23B | 2252.6 (NA to NA) | 137.2 (NA to NA) |
| 24F | 4568.0 (NA to NA) | 1346.7 (NA to NA) |
| 31 | 5040.7 (NA to NA) | 423.9 (NA to NA) |
| 35B | 10707.5 (NA to NA) | 1735.0 (NA to NA) |
The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPAs for the unique pneumococcal serotypes contained in V116 was determined. The 9 unique pneumococcal serotypes in V116 are as follows: 6A, 15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 6A | 79.1 (NA to NA) | 53.0 (NA to NA) |
| 15A | 69.7 (NA to NA) | 30.3 (NA to NA) |
| 15C | 87.9 (NA to NA) | 76.2 (NA to NA) |
| 16F | 63.2 (NA to NA) | 20.3 (NA to NA) |
| 23A | 70.6 (NA to NA) | 34.7 (NA to NA) |
| 23B | 86.6 (NA to NA) | 44.1 (NA to NA) |
| 24F | 50.5 (NA to NA) | 14.6 (NA to NA) |
| 31 | 74.4 (NA to NA) | 18.3 (NA to NA) |
| 35B | 63.8 (NA to NA) | 5.2 (NA to NA) |
OPA induced by serotypes 6A and 15C in V116 but cross-reactive to serotypes 6C and 15B, respectively, were measured. The percentage of participants with ≥4-fold rise from baseline in serotype-specific cross-reactive OPAs was determined. Point estimate, 95% CI, and p-value are based on the Clopper-Pearson method. Per protocol, this outcome measure was not planned or analyzed in the PPSV23 study arm.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 6C | 52.7 (48.7 to 56.7) | — |
| 15B | 72.6 (68.8 to 76.2) | — |
The GMFR from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined using MOPA. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.
| Ratio | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 3 | 7.5 (6.8 to 8.3) | 6.8 (6.2 to 7.5) |
| 7F | 18.3 (15.8 to 21.1) | 14.0 (12.2 to 16.1) |
| 8 | 34.3 (29.6 to 39.8) | 28.8 (25.1 to 33.0) |
| 9N | 11.3 (10.0 to 12.8) | 11.4 (10.1 to 12.8) |
| 10A | 16.6 (14.3 to 19.1) | 10.9 (9.5 to 12.4) |
| 11A | 18.5 (15.7 to 21.7) | 9.2 (7.9 to 10.8) |
| 12F | 89.2 (78.1 to 101.8) | 58.1 (50.5 to 66.8) |
| 17F | 25.2 (21.7 to 29.3) | 12.9 (11.3 to 14.8) |
| 19A | 10.2 (9.1 to 11.4) | 7.2 (6.5 to 8.0) |
| 20A | 10.9 (9.7 to 12.2) | 6.6 (5.9 to 7.3) |
| 22F | 20.5 (17.4 to 24.1) | 12.3 (10.5 to 14.3) |
| 33F | 8.8 (7.8 to 10.0) | 10.2 (9.0 to 11.6) |
| 6A | 19.5 (16.9 to 22.4) | 5.5 (4.8 to 6.3) |
| 15A | 10.4 (9.0 to 12.1) | 2.4 (2.1 to 2.7) |
| 15C | 49.4 (42.4 to 57.6) | 17.3 (15.1 to 19.8) |
| 16F | 7.0 (6.3 to 7.8) | 1.8 (1.6 to 1.9) |
| 23A | 13.9 (11.7 to 16.5) | 2.7 (2.2 to 3.2) |
| 23B | 53.9 (45.9 to 63.3) | 4.5 (3.9 to 5.2) |
| 24F | 5.5 (4.8 to 6.3) | 1.6 (1.4 to 1.8) |
| 31 | 19.5 (16.7 to 22.8) | 1.7 (1.5 to 1.9) |
| 35B | 7.0 (6.3 to 7.8) | 1.1 (1.1 to 1.2) |
The GMCs for serotype-specific IgG antibodies for all serotypes in V116 were determined using pneumococcal electrochemiluminescence (PnECL). The GMC ratio estimation and 95% CI were calculated using a cLDA method. Per protocol, within-group CIs, or any other method of dispersion were not planned or calculated.
| μg/mL | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 3 | 0.79 (NA to NA) | 0.69 (NA to NA) |
| 7F | 9.35 (NA to NA) | 5.02 (NA to NA) |
| 8 | 13.83 (NA to NA) | 11.85 (NA to NA) |
| 9N | 11.21 (NA to NA) | 7.23 (NA to NA) |
| 10A | 15.05 (NA to NA) | 7.41 (NA to NA) |
| 11A | 8.83 (NA to NA) | 4.01 (NA to NA) |
| 12F | 2.28 (NA to NA) | 1.14 (NA to NA) |
| 17F | 16.39 (NA to NA) | 6.85 (NA to NA) |
| 19A | 9.54 (NA to NA) | 6.42 (NA to NA) |
| 20A | 22.97 (NA to NA) | 12.32 (NA to NA) |
| 22F | 5.32 (NA to NA) | 3.00 (NA to NA) |
| 33F | 19.12 (NA to NA) | 15.70 (NA to NA) |
| 6A | 5.79 (NA to NA) | 1.53 (NA to NA) |
| 15A | 17.98 (NA to NA) | 2.01 (NA to NA) |
| 15C | 19.27 (NA to NA) | 5.61 (NA to NA) |
| 16F | 3.48 (NA to NA) | 0.35 (NA to NA) |
| 23A | 4.21 (NA to NA) | 0.56 (NA to NA) |
| 23B | 5.74 (NA to NA) | 1.20 (NA to NA) |
| 24F | 8.52 (NA to NA) | 0.40 (NA to NA) |
| 31 | 3.48 (NA to NA) | 0.40 (NA to NA) |
| 35B | 22.26 (NA to NA) | 1.43 (NA to NA) |
The GMFR from baseline in GMCs for serotype-specific IgG antibodies for all serotypes in V116 was determined using PnECL. The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution.
| Ratio | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 3 | 5.3 (5.0 to 5.8) | 4.7 (4.4 to 5.0) |
| 7F | 19.3 (17.5 to 21.4) | 10.9 (10.0 to 11.8) |
| 8 | 16.4 (14.9 to 18.1) | 14.1 (13.0 to 15.3) |
| 9N | 20.1 (18.1 to 22.4) | 13.3 (12.2 to 14.5) |
| 10A | 22.3 (20.2 to 24.7) | 11.1 (10.2 to 12.1) |
| 11A | 10.9 (9.8 to 12.0) | 5.0 (4.7 to 5.4) |
| 12F | 20.5 (18.4 to 22.9) | 10.6 (9.5 to 11.7) |
| 17F | 25.5 (23.1 to 28.1) | 10.8 (9.9 to 11.8) |
| 19A | 7.8 (7.1 to 8.6) | 5.3 (4.9 to 5.7) |
| 20A | 15.8 (14.4 to 17.3) | 8.6 (7.9 to 9.3) |
| 22F | 19.1 (17.3 to 21.2) | 11.0 (10.0 to 12.1) |
| 33F | 14.4 (13.1 to 15.8) | 12.0 (11.0 to 13.0) |
| 6A | 17.1 (15.3 to 19.0) | 4.6 (4.2 to 5.1) |
| 15A | 27.5 (24.9 to 30.4) | 3.1 (2.9 to 3.4) |
| 15C | 30.1 (27.1 to 33.4) | 8.8 (8.0 to 9.6) |
| 16F | 15.4 (14.1 to 16.9) | 1.6 (1.5 to 1.7) |
| 23A | 20.4 (18.4 to 22.6) | 2.8 (2.6 to 3.0) |
| 23B | 13.3 (12.0 to 14.7) | 2.9 (2.7 to 3.1) |
| 24F | 23.0 (20.8 to 25.6) | 1.1 (1.1 to 1.1) |
| 31 | 13.0 (11.9 to 14.3) | 1.6 (1.5 to 1.7) |
| 35B | 16.8 (15.3 to 18.5) | 1.1 (1.0 to 1.1) |
The percentage of participants with ≥4-fold rise from baseline in serotype-specific OPA GMTs for all serotypes in V116 was determined with MOPA. The within-group CIs were calculated based on the Clopper-Pearson method.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 3 | 69.2 (65.4 to 72.9) | 66.9 (62.9 to 70.7) |
| 7F | 75.2 (71.7 to 78.5) | 69.9 (66.2 to 73.4) |
| 8 | 83.6 (80.5 to 86.3) | 85.4 (82.5 to 88.0) |
| 9N | 72.3 (68.6 to 75.9) | 73.3 (69.5 to 76.8) |
| 10A | 74.7 (71.1 to 78.1) | 66.5 (62.6 to 70.2) |
| 11A | 72.1 (68.4 to 75.5) | 58.8 (54.9 to 62.6) |
| 12F | 93.3 (91.1 to 95.0) | 90.7 (88.3 to 92.8) |
| 17F | 84.1 (80.9 to 87.0) | 71.8 (68.0 to 75.3) |
| 19A | 70.9 (67.3 to 74.3) | 64.1 (60.3 to 67.7) |
| 20A | 71.0 (67.5 to 74.4) | 58.1 (54.3 to 61.8) |
| 22F | 76.5 (72.9 to 79.8) | 67.2 (63.3 to 70.9) |
| 33F | 66.2 (62.2 to 70.0) | 70.9 (67.1 to 74.5) |
| 6A | 79.1 (75.7 to 82.2) | 53.0 (49.0 to 57.0) |
| 15A | 69.7 (65.6 to 73.6) | 30.3 (26.4 to 34.5) |
| 15C | 87.9 (85.1 to 90.3) | 76.2 (72.7 to 79.4) |
| 16F | 63.2 (59.3 to 67.1) | 20.3 (17.2 to 23.7) |
| 23A | 70.6 (66.3 to 74.6) | 34.7 (30.2 to 39.5) |
| 23B | 86.6 (83.7 to 89.1) | 44.1 (40.2 to 48.1) |
| 24F | 50.5 (46.2 to 54.7) | 14.6 (11.6 to 18.0) |
| 31 | 74.4 (70.8 to 77.7) | 18.3 (15.4 to 21.4) |
| 35B | 63.8 (60.0 to 67.5) | 5.2 (3.6 to 7.1) |
The percentage of participants with ≥4-fold rise from baseline in serotype-specific IgG GMCs for all serotypes in V116 was determined using PnECL. The within-group CIs were calculated based on the Clopper-Pearson method.
| Percentage of Participants | Base Study: V116 | Base Study: PPSV23 |
|---|---|---|
| 3 | 59.8 (56.1 to 63.4) | 54.7 (51.0 to 58.4) |
| 7F | 84.8 (81.9 to 87.4) | 79.7 (76.6 to 82.6) |
| 8 | 84.4 (81.5 to 87.0) | 86.5 (83.7 to 88.9) |
| 9N | 85.5 (82.7 to 88.0) | 83.2 (80.3 to 85.9) |
| 10A | 88.9 (86.3 to 91.1) | 81.1 (78.1 to 83.9) |
| 11A | 76.8 (73.5 to 79.8) | 56.6 (52.8 to 60.2) |
| 12F | 86.5 (83.7 to 88.9) | 73.7 (70.4 to 76.9) |
| 17F | 91.0 (88.6 to 93.0) | 79.6 (76.5 to 82.5) |
| 19A | 63.9 (60.3 to 67.5) | 58.5 (54.8 to 62.2) |
| 20A | 85.5 (82.7 to 88.0) | 73.3 (69.9 to 76.5) |
| 22F | 85.4 (82.5 to 87.9) | 77.5 (74.3 to 80.5) |
| 33F | 83.0 (80.0 to 85.7) | 83.5 (80.6 to 86.2) |
| 6A | 81.4 (78.3 to 84.2) | 47.3 (43.6 to 51.1) |
| 15A | 91.3 (88.9 to 93.2) | 34.2 (30.7 to 37.8) |
| 15C | 90.7 (88.3 to 92.7) | 72.1 (68.6 to 75.3) |
| 16F | 83.8 (80.9 to 86.4) | 11.3 (9.1 to 13.9) |
| 23A | 85.9 (83.1 to 88.4) | 29.9 (26.6 to 33.4) |
| 23B | 78.9 (75.7 to 81.8) | 33.1 (29.7 to 36.7) |
| 24F | 88.2 (85.5 to 90.4) | 1.7 (0.9 to 2.9) |
| 31 | 82.0 (78.9 to 84.7) | 11.6 (9.3 to 14.2) |
| 35B | 85.1 (82.2 to 87.6) | 2.1 (1.2 to 3.4) |
Collected over Up to 24 months postvaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study: V116 | 0/741 (0%) | 22/739 (3%) | 399/739 (54%) |
| Base Study: PPSV23 | 0/743 (0%) | 18/741 (2.4%) | 364/741 (49.1%) |
| Immunogenicity Substudy: V116 | 0/349 (0%) | 0/349 (0%) | 0/349 (0%) |
| Immunogenicity Substudy: PPSV23 | 0/348 (0%) | 0/348 (0%) | 0/348 (0%) |
| PBMC Sub-study: V116 | 0/41 (0%) | 0/41 (0%) | 0/41 (0%) |
| PBMC Sub-study: PPSV23 | 0/39 (0%) | 0/39 (0%) | 0/39 (0%) |
| Event | Base Study: V116 | Base Study: PPSV23 | Immunogenicity Substudy: V116 | Immunogenicity Substudy: PPSV23 | PBMC Sub-study: V116 | PBMC Sub-study: PPSV23 |
|---|---|---|---|---|---|---|
| ExtrasystolesCardiac disorders | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Mitral valve incompetenceCardiac disorders | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Sinus bradycardiaCardiac disorders | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Thyroid massEndocrine disorders | 1/739 | 1/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Abdominal wall haematomaGastrointestinal disorders | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Chest painGeneral disorders | 1/739 | 1/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| CholecystitisHepatobiliary disorders | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Abdominal infectionInfections and infestations | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| InfluenzaInfections and infestations | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Osteomyelitis chronicInfections and infestations | 1/739 | 0/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Event | Base Study: V116 | Base Study: PPSV23 | Immunogenicity Substudy: V116 | Immunogenicity Substudy: PPSV23 | PBMC Sub-study: V116 | PBMC Sub-study: PPSV23 |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 301/739 | 261/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| HeadacheNervous system disorders | 124/739 | 105/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| FatigueGeneral disorders | 122/739 | 118/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Injection site erythemaGeneral disorders | 58/739 | 47/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Injection site swellingGeneral disorders | 48/739 | 32/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| MyalgiaMusculoskeletal and connective tissue disorders | 43/739 | 46/741 | 0/349 | 0/348 | 0/41 | 0/39 |
| Age, Continuous(Years) | Base Study: V116 | Base Study: PPSV23 | Total |
|---|---|---|---|
| Mean | 63.9 ± 8.4 | 63.7 ± 8.3 | 63.8 ± 8.3 |
| Sex: Female, Male(Participants) | Base Study: V116 | Base Study: PPSV23 | Total |
|---|---|---|---|
| Female | 332 | 333 | 665 |
| Male | 409 | 410 | 819 |
| Ethnicity (NIH/OMB)(Participants) | Base Study: V116 | Base Study: PPSV23 | Total |
|---|---|---|---|
| Hispanic or Latino | 151 | 162 | 313 |
| Not Hispanic or Latino | 579 | 571 | 1150 |
| Unknown or Not Reported | 11 | 10 | 21 |
| Race (NIH/OMB)(Participants) | Base Study: V116 | Base Study: PPSV23 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 5 | 9 |
| Asian | 151 | 140 | 291 |
| Native Hawaiian or Other Pacific Islander | 9 | 3 | 12 |
| Black or African American | 2 | 2 | 4 |
| White | 455 | 469 | 924 |
| More than one race | 119 | 124 | 243 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2022 to primary completion in Oct 2023, 11 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 11 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine